Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 5/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773707 | 0.83 | CNR2 (0.33) | POLBL3MBTL1CNR2CNR1KDM4E | |
| SCHEMBL4772142 | 0.74 | SCN4A (0.46) | CNR2CNR1KDM4EALDH1A1 | |
| SCHEMBL4772136 | 0.74 | SCN4A (0.46) | CNR2CNR1KDM4EALDH1A1 | |
| SCHEMBL4768331 | 0.68 | KDM4E (0.46) | TSHRKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL4770430 | 0.68 | KDM4E (0.41) | TSHRPOLBL3MBTL1KDM4ECASP1 | |
| SCHEMBL17477692 | 0.63 | BRD4 (0.51) | CNR2CNR1KDM4EBRD4BRD2 | |
| SCHEMBL31186177 | 0.62 | L3MBTL1 (0.41) | POLBL3MBTL1KDM4ECASP1CASP7 | |
| SCHEMBL2280624 | 0.62 | ALDH1A1 (0.46) | TSHRPOLBL3MBTL1KDM4ECASP1 | |
| Hydrochloric Acid SCHEMBL11535108 | 0.62 | BRD4 (0.50) | POLBCNR2CNR1KDM4EBRD4 | |
| SCHEMBL11634695 | 0.62 | PTGS2 (0.45) | TSHRPOLBL3MBTL1KDM4ECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878704-B2 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058937-A1 | Heterocyclic mutilin esters and their use as antibacterials | MLN, MSH2, MRPL21 | TSHR 3115/4885POLB 150/4885L3MBTL1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.